Hofseth Biocare ASA: New study and US provisional patent filed on regulation of oxidative protective genes in human cells with ProGo for treatment of IBD, such as ulcerative colitis and Crohn's

An invitro study on the regulation of oxidative protective genes in human gingival and intestinal epithelial cells after treatment with salmon protein hydrolysate peptides has been published in the journal Functional Foods in Health and Disease (2018; 8(8): 353-366). HBC has also recently filed a provisional US patent covering these results.

This study measured the up/down regulation of 84 oxidative protective genes within human gingival epithelial cells and human intestinal epithelial cells when treated with varying concentrations of ProGo® (HBC salmon protein hydrolysate) solution.

The regulation of oxidative stress-related genes as a possible mechanism that can confer cyto-protection to tissues exposed to oxidative injury has been the subject of investigation by many researchers.

While molecular oxygen is essential for the survival of almost all eukaryotes, its processing under physiological conditions generates reactive oxygen species (ROS) such as hydrogen peroxide, superoxide, peroxy nitrite, and hydroxyl radicals, as metabolic by-products. In the absence of an adequate defense mechanism, the accumulation of ROS and other electrophiles leads to cell membrane and DNA damage, mutagenicity, degeneration of tissues, premature aging, apoptotic cell death, and cancers. To combat excess ROS, cells have developed an array of inducible defensive gene activations which results in a neutralization of the oxidative stress, reduced ROS, and thereby increased cell survival.

Results from this study conclude that ProGo® powder contains bioactive peptides that changes the regulation of several oxidative protective genes in two different human epithelial cells. The unusually high number of genes shown to be impacted may be a direct result of the over 250 peptides of certain molecular weights in ProGo® developed by HBC over the last ten years, that could act as gene modulators.

Three genes also showed a dose-dependent response to ProGo®, the FTH1, HMOX1 and ALOX12 genes. The upregulation in the HMOX1 gene, particularly in intestinal epithelial cells, is being used by HBC to guide the development of a functional food that can confer a protective effect on the gastrointestinal tract. Such a product may be used, in conjunction with medical treatment, for the control of Inflammatory Bowel Disease (IBD), such as ulcerative colitis, enterocolitis and Crohn's disease.

For more information, please contact:

Dr. Bomi Framroze, CSO at Hofseth BioCare ASA

bf@hofsethbiocare.no

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

 
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.